A bipartisan bill reintroduced by three senators aims to increase transparency around foreign influence on the United States’ ...

Since reaching the market a decade ago, PCSK9 inhibitors have not lived up to their lofty expectations. | The FDA has ...

As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new ...

In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish ...

Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. | Merck & Co.’s almighty ...

Red-hot generative AI specialist Insilico Medicine has teamed up with another major biopharma player, this time linking up ...

The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), ...

After a 7% increase in revenue for the second quarter, which came on the heels of a 10% gain in Q1, Johnson & Johnson has bumped up its annual sales guidance. The company now projects 2026 revenue at ...

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...

Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase ...

After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have ...

Insulet’s wearable insulin patch Omnipod may be able to seamlessly control insulin delivery for patients with diabetes, but ...